National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) for RCC.

 

NCPE Assessment Process Completed
Rapid review commissioned 28/11/2018
Rapid review completed 11/12/2018
Rapid Review outcome Full pharmacoeconomic assessment is recommended
HTA commissioned by the HSE 19/12/2018
Pre-submission consultation with Applicant 28/01/2019
Submission received from Applicant 01/04/2019
NCPE assessment commenced 17/07/2019
Preliminary review sent to Applicant 23/09/2019
NCPE assessment re-commenced 21/10/2019
Factual accuracy sent to Applicant 28/11/2019
NCPE assessment re-commenced 06/12/2019
NCPE assessment completed 07/01/2020
NCPE assessment outcome The NCPE recommends that nivolumab in combination with ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.